Medical Cannabis Momentum Avicanna has an established medical cannabis and wellness brand (RHO Phyto) with nationwide Canada availability and ongoing expansion into international markets, presenting opportunities to license, co-market, or supply chain partnerships with healthcare providers and pharmacies in new regions.

Pharmaceutical Pipeline A diverse pipeline of indication-specific cannabinoid drug candidates in various clinical stages offers potential B2B collaboration, licensing, or contract manufacturing opportunities with pharmaceutical partners seeking dermatology, chronic pain, and neurology solutions.

Clinical Education Platform MyMedi.ca and pharmacist-led patient support programs create channels to engage medical professionals and payers, enabling partnerships for education, adherence programs, and reimbursement pathways to broaden patient access and drive product uptake.

International Expansion Recent leadership change and announced U.S. expansion plus plan to broaden international footprint indicate opportunities for channel development, strategic alliances, and market entry services for distributors, clinics, and medical institutions in new jurisdictions.

Financial & Growth Signals Revenue in the low-to-mid range with a significant funding runway, combined with a high-value research platform, suggests opportunities to pitch strategic investments, co-development deals, and grant-backed programs to accelerate commercialization and scale manufacturing.